相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
Sophie Hallakou-Bozec et al.
DIABETES OBESITY & METABOLISM (2021)
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
Julie Dubourg et al.
DIABETES OBESITY & METABOLISM (2021)
Imeglimin: Current Development and Future Potential in Type 2 Diabetes
Chigoziri Konkwo et al.
DRUGS (2021)
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Julie Dubourg et al.
DIABETES CARE (2021)
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
Sophie Hallakou-Bozec et al.
PLOS ONE (2021)
Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats
Sophie Hallakou-Bozec et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2021)
The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
Guillaume Vial et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2021)
Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
Clemence Chevalier et al.
CLINICAL PHARMACOKINETICS (2021)
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects
Pascale Fouqueray et al.
CLINICAL PHARMACOKINETICS (2020)
Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus
Julie Dubourg et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans
Chevalier Clemence et al.
DRUG METABOLISM AND DISPOSITION (2020)
Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers
Clemence Chevalier et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2020)
Imeglimin Protects INS-1 Cells and Human Islets against High Glucose- and High Fructose-Induced Cell Death by Inhibiting the Mitochondrial PTP Opening
Sandrine Lablanche et al.
DIABETES (2018)
Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents
Rachel J. Perry et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes
G. Pacini et al.
DIABETES OBESITY & METABOLISM (2015)
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
Valerie Vuylsteke et al.
DRUGS IN R&D (2015)
Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model
Guillaume Vial et al.
DIABETES (2015)
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy
Pascale Fouqueray et al.
DIABETES CARE (2014)
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Pascale Fouqueray et al.
DIABETES CARE (2013)
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
V. Pirags et al.
DIABETES OBESITY & METABOLISM (2012)
分享论文
